LGALS9 and cancer: Additionally, resistance to PD-1/PD-L1 ICIs may also be influenced by molecules that modulate PD-1 signaling to promote immune escape, such as galectin-9 (Gal-9), implicating such proteins as putative targets for cancer immunotherapy [89,90].